Control patients showed worsening of fluorescein leakage over the observation period of four to six weeks whereas the other six patients given the somatostatin infu sion did not demonstrate any deterioration.
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The mechanism of action of somatostatin in this study is unknown but it is thought to have direct anti-angiogenic properties as well as inhibiting growth hormone secretion.
Numerous clinical reports have postulated growth hormone (GH) as an aetiological agent in the pathogenesis of proliferative dia betic retinopathy. l-5 The aetiology of diabetic microvascular complications appears to be multifactorial and is poorly defined. It is widely agreed that poor metabolic control predisposes to these complications but the link between diabetic control and their development is not yet fully understood. Cir culating GH has an effect on glucose metab olism causing insulin resistance with resultant glucose intolerance, hyperglycaemia and increased insulin requirement. 6 Type I dia betic patients have been reported to produce increased levels of circulating GH,x especially during periods of poor metabolic control. 7
In 1953 Poulsen reported an improvement in proliferative diabetic retinopathy in a patient who suffered a post-partum pituitary infarction. 5 Following this observation, thera peutic pituitary ablation was introduced!A to produce regression of severe proliferative ret inopathy. The degree of regression obtained was reported to be directly related to the degree of pituitary ablation and GH defi ciency producedY·1II Further observations lending support to the postulated relationship between GH and diabetic retinopathy fol lowed. Retinopathy was reported as absent or only mild, in pituitary dwarfs with diabetes.2 In poorly controlled diabetics raised GH levels are invariably found!! and an abnormal increase in GH secretion has also been noted with exercise12 and during sleep. This is the same group in which diabetic retinopathy is more likely to be found. 
Selective pharmacological inhibition of GH

Patients and Methods
Seventeen adult patients with insulin depend ent diabetes and proliferative retinopathy were recruited. Six of these patients were con trols. As the study was a pilot project, the patients were not randomised. The age range of these patients was 25 to 58 years.
The inclusion criteria were:
(1) insulin dependent diabetes, (2) proliferative retinopathy where the neo vascular tissue was in isolated patches in the periphery in less than two quadrants in the periphery or occupied less than or equal to a quarter of the disc with no vit reous or pre-retinal haemorrhage (low risk-DRS definition) (3) ability to modify own dose of insulin.
The exclusion criteria were:
(1) florid proliferative retinopathy, greater than two quadrants or involving more than a quarter of the disc, (2) proliferative retinopathy with either vit reous or pre-retinal haemorrhage (high risk-DRS definition), (3) non-insulin dependent diabetic patients, assays were performed as part of the study. All patients were then reviewed at Moor fields Eye Hospital at four weeks following commencement of BIM23014, then at six and/or eight weeks and 12 weeks. Clinical assessment of the retina was repeated as were colour fundus photography and fluorescein angiography. The control group patients were seen at the same time intervals and had the same assessment as the patients given BIM23014. There was no significant differ ence in diabetic control between the subjects and the controls. Rather than a complete fun dus photographic survey being undertaken to obtain serial frames of an area of prolifer ation, one or two areas of interest were identi fied in one eye and these same areas were photographed at each examination.l Frames from each angiogram, taken at the same time in the fluorescein run, were then compared.
In particular, the early frames were the most useful as the area to be studied was not swamped with fluorescein. At the first four week visit the eye was treated with argon laser pametinal photocoagulation (PRP) if there was no significant regression of retinal neo vascularisation clinically or angiographically. Angiographic resultsireports were based on a subjective, assessment of the alteration in flu orescein leakage at a specified site.
Results
Eleven patients were commenced on the continuous infusion pump. In this group, GH was found to be completely suppressed in day time assays. Plasma levels of BIM23014 were always above 3ng/ml. Levels of more than 1.5 ng/ml have been shown to completely sup press GH in studies on acromegalic patients.
Pretreatment levels of IGF-1 were below the normal range (0.42+/-0.06 units/ml) and further suppression was obtained with treat ment (0.27+/-0.04 units/ml) after six weeks.
This further suppression suggests significant reduction of GH secretion. Insulin require ments were reduced on average by 20-25% , but despite this HbA-1 levels were unaffected (10.7+/-0.8% before and 9.43+/-0.67% after treatment). Despite the diminished insulin requirements, no patient reported hypoglycaemic episodes. Some of the patients did complain of abdominal discomfort and increased bowel movements but this usually improved during the course of the study.
Eight patients continued with the subcuta neous infusion pumps for at least four weeks. Two patients then withdrew. One withdrew following repeated skin infections at the pump cannula site and another due to diffi culty managing the pump. Three patients withdrew prior to complet ing the first four weeks due to difficulty in managing the pump.
Visual acuity did not alter in either the con trol group or in the group receiving pump treatment over the period of the trial. Vit reous or preretinal haemorrhage did not occur over the first four weeks prior to laser treatment in either group.
Of the eight patients who received Somatu line via subcutaneous pumps, two showed clinical and angiographic improvement and were not treated with laser at four weeks. (Figure 2a) . There was no evidence of pre-retinal or vitreous haemorrhage in either eye and ophthalmo scopically the new vessels at the disc remained unchanged. Angiograms performed after four weeks of Somatuline (Fig. 2b) showed a mild reduction in the area of fluorescein leakage from the disc new vessels when compared to pre-treatment films. More noticeably there was less capillary non-perfusion on the post treatment angiogram in areas temporal and superonasal to the disc.
Discussion
Eight of the 11 patients, commenced on the BM23014 infusion pumps, were evaluated at four weeks by ophthalmoscopic and angio graphic examination. During this four to six week period no laser treatment was given. In These were all treated with PRP in the usual way. Although these patients continued with BM23014 (Somatuline) the angiograms taken following laser were of less value when attempting to assess the effect of Somatuline as it could be argued that any subsequent improvement was related to the laser treatment.
Improvement on Somatuline occurred in two out of eight patients which is a higher pro portion than would have been expected to spontaneously or naturally regress without treatment.
With PRP established as an effective widely available treatment for proliferative retino pathy, somatostatin analogue therapy would have to display a greater success rate than is suggested in this pilot study. However PRP is II destructive treatment with side-effects and does have limitations as a form of treatment in some elinical situations. The numbers in this study are too small to draw a statistical con- elusion. Despite this, it is interesting to note that there was no deterioration in the ret inopathy in the treated group whereas in the control group, three of the six patients showed increased fluorescein leakage at the four week review.
In this study, IGF-l levels were suppressed by Somatuline. However, it has not been unequivocally shown that somatostatin analo gues act on the pituitary to effect any improvement in retinopathy. Indeed somatos tatin analogues may act at the retinal level to inhibit the activity of GH and IGF-l locally rather than at the level of the pituitary. Recently, somatostatin analogues have been reported to inhibit angiogenesis in the chick chorioallantoic membrane.2K If the main inhibitory action does occur peripherally at the level of the retina, then an adequate thera peutic dose to improve retinopathy may not be related to that suppressing GH, and may need to be higher than that used in this study.
Another potential area of study would be the role of Somatuline as an adjunct to PRP rather than as a replacement for it. Patients in which PRP can not be applied or applied only in a limited fashion, due to vitreous haemor rhage, media opacity or patient intolerance to laser, may be helped by a trial of pharmac ological inhibition of growth hormone.
In summary, in a pilot study we were able to 
